Mel Walker and Yngve Mikkelsen join the NDA Advisory Board
Mel utilizes his extensive experience in strategy development to enable companies to achieve success by integrating commercial and patient access requirements at earlier phases of drug development, including Advanced Therapy Medicinal Products (ATMP). His areas of expertise include deep knowledge of European Payer and HTA systems and strategies that optimize value proposition, pricing, reimbursement, patient access and product uptake.
His experience allows him to support clients to better understand their strategic HTA options from TPP development to post-authorisation phase.
Mel, who has held senior leadership roles at Roche, GSK and Otsuka during his 20+ years in the industry says, “NDA are a very well-respected brand in the regulatory field, and I am excited about further developing the HTA aspect of their advisory capabilities and the considerable impact that can be delivered for small companies that lack these capabilities.”